IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis

M. Vis, W.H. Bos, G. Wolbink, A.E. Voskuijl, J.W.R. Twisk, R van de Stadt, D. Hamann, B.A.C. Dijkmans, W.F. Lems

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)425-428
JournalJournal of Rheumatology
Volume35
Issue number3
Publication statusPublished - 2008

Cite this